DRUG RELATED PROBLEMS IN EMERGENCY DEPARTMENT PATIENTS: ROLE OF CLINICAL PHARMACIST
CP-132
MEDICATION ERRORS AND THEIR SEVERITY DETECTED IN THE OBSERVATION AREA OF AN EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL
CP-127
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS FORMULATION OF TRASTUZUMAB: COSTS AND SAFETY
CP-123
A COST EFFECTIVENESS ANALYSIS OF NIVOLUMAB COMPARED WITH PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN REAL PRACTICE
CP-118
DOES A STRUCTURED PROTOCOL INCREASE IMPLEMENTATION OF BIOLOGIC THERAPY DOSE REDUCTION AMONG CLINICIANS AND PATIENTS? A PILOT STUDY
CP-115
OPTIMISATION OF ANTI-INTERLEUKIN BIOLOGICAL THERAPIES IN PSORIASIS PATIENT ABOVE 100 KG
CP-114
PERSISTENCE OF BIOLOGICAL TREATMENT IN PATIENTS WITH PSORIASIS
CP-112
A MULTIDISCIPLINARY APPROACH TO ANTIRETROVIRAL SIMPLIFICATION IN HIV-INFECTED PATIENTS
CP-110
MULTIDISCIPLINARY VIEWS TOWARDS THE CLINICAL PHARMACIST: A Hospital Palliative Care Team Perspective
CP-109
EVALUATION OF CLINICAL, ECONOMIC AND ORGANISATIONAL IMPACTS OF PHARMACISTS' INTERVENTIONS IN IMMUNOSUPPRESSIVE THERAPY MANAGEMENT AMONG LUNG TRANSPLANT OUTPATIENTS
CP-102
USEFULNESS OF THE TRACEABILITY OF PHARMACEUTICAL ANALYSIS IN PATIENT'S MEDICAL RECORD
CP-101
NATALIZUMAB EVERY 6 WEEKS VERSUS STANDARD DOSE: EVALUATION OF EFFECTIVENESS. PRELIMINARY STUDY
CP-099
IMPLEMENTATION OF A STRUCTURED OUTPATIENT PARENTERAL ANTIMICROBIAL THERAPY (OPAT) SERVICE BY THE HOSPITAL PHARMACIST IN A REGIONAL HOSPITAL
CP-093
THE IMPACT OF MYELOMA MULTIPLE CLINICAL TRIALS ON MEDICATION COST SAVINGS
CP-090
EVALUATION OF EFFICACY AND SAFETY OF REGORAFENIB IN METASTATIC COLON CANCER
